SLC5A2 and congenital rubella syndrome: Recent advances in the treatment of CRS have highlighted the potential of novel therapeutic approaches, such as sodium-glucose-cotransporter-2 (SGLT2) inhibitors and intermittent fasting, in mitigating oxidative stress and improving clinical outcomes.